Helen M. Thackray - Apr 1, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief R&D Officer
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Apr 1, 2022
Transactions value $
-$123,120
Form type
4
Date filed
4/4/2022, 04:32 PM
Previous filing
Dec 16, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Sale -$123K -7.6K -5.28% $16.20 136K Apr 1, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022.
F2 Shares sold to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2021.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.09 to $16.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.